Recent research have centered on the intersection of GLP-1|GIP|glucagon receptor activator therapies and dopaminergic communication. While GLP stimulators are increasingly employed for addressing type 2 diabetes mellitus, their emerging consequences on reward circuits, specifically mediated by dopaminergic systems, are receiving significant attenti